Overview

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Gabrail Cancer Center Research
Collaborators:
Karyopharm Therapeutics Inc
Karyopharm Therapeutics, Inc